Moderna, Inc. (MRNA) Stock Forecast
MRNA analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.13 / 5 from 23 analysts
- Price target
- $123.61 average of analyst targets
- Upside to target
- −43.3% from the latest close
- Next earnings
- November 6, 2026 EPS estimate $-1.10
- 52-week range
- $22.36 – $236.50
MRNA analyst ratings
23 analystsNumber of analysts at each rating.
MRNA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MRNA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.26 | −$3.28 | −$0.53 | −$0.51 | −147.7% | 15 |
| Current fiscal year (2026) | −$8.38 | −$10.57 | −$6.66 | −$7.26 | −15.4% | 21 |
| Next fiscal year (2027) | −$4.78 | −$7.11 | −$2.73 | −$8.38 | +43.0% | 20 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MRNA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $892.4M | $836.0M | $1.12B | −12.2% | 14 |
| Current fiscal year (2026) | $2.10B | $1.96B | $2.15B | +8.1% | 21 |
| Next fiscal year (2027) | $2.44B | $1.92B | $3.29B | +16.1% | 19 |
MRNA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MRNA revenue: reported and forecast
MRNA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.23 | −$1.35 | −$1.29 | −$1.27 | −$1.26 | +2.9% | 3 up · 0 down |
| Current fiscal year (2026) | −$8.67 | −$8.58 | −$8.38 | −$8.39 | −$8.38 | −3.3% | 2 up · 1 down |
| Next fiscal year (2027) | −$4.76 | −$4.91 | −$4.79 | −$4.79 | −$4.78 | +0.4% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MRNA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MRNA beat in 9 of 12.
What analysts expect from MRNA
23 analysts cover Moderna; their consensus rating is hold (3.13 on a 1–5 scale, where 5 is a strong buy). The average price target is $123.61, 43.3% below the latest close of $218.01. Analysts expect earnings of −$8.38 per share for 2026, −15.4% from a year earlier. For 2027 the average estimate is −$4.78 per share on revenue of $2.4 billion. Moderna beat the EPS estimate in 9 of the last 12 quarters.
Related: MRNA income statement, MRNA key metrics, MRNA chart. See the MRNA stock overview for the latest quote and news.
MRNA forecast FAQ
What is Moderna's price target?
The average analyst price target for Moderna is $123.61, 43.3% below the latest close of $218.01.
Is Moderna a buy, hold or sell?
Of 23 analysts covering Moderna, 4 rate it a strong buy, 1 a buy, 14 a hold, 2 a sell and 2 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Moderna's EPS forecast?
Analysts forecast −$8.38 per share for 2026 (range −$10.57 to −$6.66); for 2027 the estimate is −$4.78.
What is Moderna's revenue forecast?
The average revenue estimate for 2026 is $2.1 billion, growth of 8.1%; for 2027 it is $2.4 billion.
When does Moderna report earnings?
Moderna is expected to report results for the quarter ending September 30, 2026 on November 6, 2026 before the market opens; the EPS estimate is $-1.10.
Does Moderna usually beat earnings estimates?
Moderna reported EPS at or above the analyst estimate in 9 of the last 12 quarters.